Geneva Partners LLC acquired a new position in shares of ABIOMED, Inc. (NASDAQ:ABMD) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 2,755 shares of the medical equipment provider’s stock, valued at approximately $464,000.
A number of other large investors have also recently bought and sold shares of ABMD. Koch Industries Inc. increased its stake in ABIOMED by 40,431.3% during the 2nd quarter. Koch Industries Inc. now owns 799,277 shares of the medical equipment provider’s stock worth $794,000 after buying an additional 797,305 shares in the last quarter. Baillie Gifford & Co. increased its stake in ABIOMED by 17.9% during the 2nd quarter. Baillie Gifford & Co. now owns 1,971,690 shares of the medical equipment provider’s stock worth $282,543,000 after buying an additional 299,255 shares in the last quarter. American Century Companies Inc. increased its stake in ABIOMED by 99.8% during the 3rd quarter. American Century Companies Inc. now owns 484,142 shares of the medical equipment provider’s stock worth $81,626,000 after buying an additional 241,868 shares in the last quarter. FMR LLC purchased a new stake in ABIOMED during the 2nd quarter worth approximately $32,609,000. Finally, Renaissance Technologies LLC increased its stake in ABIOMED by 33.6% during the 2nd quarter. Renaissance Technologies LLC now owns 893,223 shares of the medical equipment provider’s stock worth $127,999,000 after buying an additional 224,523 shares in the last quarter. Institutional investors own 90.74% of the company’s stock.
Several equities research analysts have commented on the company. BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a research note on Thursday, August 10th. Jefferies Group LLC boosted their target price on ABIOMED from $175.00 to $208.00 and gave the stock a “buy” rating in a report on Friday, September 29th. SunTrust Banks, Inc. restated a “buy” rating and set a $195.00 target price on shares of ABIOMED in a report on Wednesday, November 1st. BTIG Research restated a “hold” rating on shares of ABIOMED in a report on Sunday, October 29th. Finally, Zacks Investment Research upgraded ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 target price on the stock in a report on Tuesday, November 7th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. ABIOMED has a consensus rating of “Buy” and a consensus target price of $185.38.
ILLEGAL ACTIVITY WARNING: “Geneva Partners LLC Takes Position in ABIOMED, Inc. (ABMD)” was first reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.truebluetribune.com/2017/11/20/geneva-partners-llc-takes-position-in-abiomed-inc-abmd.html.
Shares of ABIOMED, Inc. (NASDAQ ABMD) traded down $0.59 during trading on Monday, hitting $194.32. The stock had a trading volume of 448,700 shares, compared to its average volume of 337,822. ABIOMED, Inc. has a fifty-two week low of $103.53 and a fifty-two week high of $198.29. The firm has a market cap of $8,590.00, a PE ratio of 124.56, a P/E/G ratio of 2.59 and a beta of 0.23. The company has a current ratio of 5.84, a quick ratio of 5.20 and a debt-to-equity ratio of 0.02.
ABIOMED (NASDAQ:ABMD) last released its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.16. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. The firm had revenue of $132.80 million for the quarter, compared to analysts’ expectations of $131.18 million. During the same period in the prior year, the firm posted $0.20 earnings per share. The firm’s quarterly revenue was up 28.9% on a year-over-year basis. research analysts forecast that ABIOMED, Inc. will post 2.38 earnings per share for the current fiscal year.
In related news, VP Andrew J. Greenfield sold 11,282 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $169.32, for a total value of $1,910,268.24. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Dorothy E. Puhy sold 6,364 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $179.08, for a total value of $1,139,665.12. Following the completion of the transaction, the director now owns 39,532 shares in the company, valued at $7,079,390.56. The disclosure for this sale can be found here. Insiders sold 51,646 shares of company stock worth $8,456,680 over the last quarter. 7.00% of the stock is currently owned by insiders.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.